IMR Press / JOMH / Special Issues / 1411917399282597888

Biomarkers for Prostate Cancer

Submission deadline: 30 August 2022
Special Issue Editors
Pierre-Jean Lamy, MD
Institut d'analyse génomique-Imagenome, Labosud, Montpellier, France
Interests: Cancer biomarkers
Special Issue Information

Dear colleagues,

Prostate cancer is the most common cancer in men. The median age of diagnosis is just before the age of 70, and the five-year survival rate is 94%. Prostate cancer generally presents a good prognosis, and it can, thus, be discussed with the patient of whether to avoid a diagnostic biopsy in certain clinical situations of suspected prostate cancer. In the case of a positive biopsy, there are different options to consider, such as active surveillance, watchful waiting, or the initiation of local treatment. To guide the patient’s choice between these options, it is necessary to determine the prognosis of the disease and define the stage of the cancer. Prostate cancer staging is based on the tumor extent using TNM categories, the PSA level and the Gleason score (Grade group). Risk groups, based on PSA, digital rectal examination, and biopsy, from very low to very high are used to determine treatment options, but they are not perfect indicators of the risk. There are ongoing efforts to develop new biomarkers, based on blood or tissue testing, that can aid clinicians in determining which cancers are supposed to be aggressive and need specific treatment.

Biomarkers could also be used to improve the early detection of prostate cancer, to avoid negative biopsies and other diagnoses, to avoid repeated biopsies, and to reduce the number of different diagnostic procedures (MRI, biopsy, other biomarkers, etc.). Recently, targeted therapies have been developed to treat metastatic prostate cancers, and biomarkers predictive of response or resistance to these treatments could be used for the management of these patients. There is currently a need to technically and clinically validate these biomarkers. This Special Issue will focus on the evaluation of the use of new biomarkers in different clinical settings to improve prostate cancer management.

Dr. Pierre-Jean Lamy

Guest Editor

Keywords
Biology
Prostate
Cancer
Biomarkers
Prognostic
Prediction
Protein
Molecular biomarkers
Oncogenetics
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://jour.ipublishment.com/imr/access/login by registering and logging in to this website. Once you are registered, click here to start your submission Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted papers should be well formatted and use good English.

Published Paper (2 Papers)
9
Download
36
Views
Open Access Original Research
16α-hydroxyestrone and its receptor complex: high affinity antigen for antibodies from prostate cancer patients
Wahid Ali Khan, Mohd. Wajid Ali Khan
J. Mens. Health 2021, 17(4), 117–127; https://doi.org/10.31083/jomh.2021.103
(This article belongs to the Special Issue Biomarkers for Prostate Cancer)
2
Download
10
Views
Back to top